Comparing Ocata Therapeutics (OCAT) & Its Competitors
Ocata Therapeutics (NASDAQ: OCAT) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Ocata Therapeutics to similar companies based on the strength of its dividends, risk, earnings, valuation, profitability, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Ocata Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ocata Therapeutics Competitors||$290.27 million||$35.99 million||59.27|
This table compares Ocata Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ocata Therapeutics Competitors||-5,189.81%||-162.78%||-35.24%|
Insider and Institutional Ownership
49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of recent ratings for Ocata Therapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ocata Therapeutics Competitors||917||3337||11837||237||2.70|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.32%. Given Ocata Therapeutics’ competitors higher possible upside, analysts plainly believe Ocata Therapeutics has less favorable growth aspects than its competitors.
Ocata Therapeutics competitors beat Ocata Therapeutics on 6 of the 8 factors compared.
About Ocata Therapeutics
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Receive News & Ratings for Ocata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.